Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia

Erden Atilla, 1 Pinar Ataca, 1 Elif Ozyurek, 2 Ilhan Erden, 2 and Gunhan Gurman 1

1Department of Hematology, Ankara University School of Medicine, 06590 Ankara, Turkey
2Department of Radiology, Ankara University School of Medicine, 06590 Ankara, Turkey

Correspondence should be addressed to Erden Atilla; erdenatilla@gmail.com

Received 2 July 2015; Revised 5 October 2015; Accepted 5 November 2015

1. Introduction

Tyrosine kinase inhibitors (TKIs) have created a new paradigm in chronic myeloid leukemia (CML) treatment. In brief, TKIs inhibit BCR-ABL oncoproteins in patients with Philadelphia chromosome positive (Ph+) CML and acute lymphoblastic leukemia (ALL) [1]. The Ph+ chromosome is detected in 95% of CML cases, whereas it is detected in 5–49% of ALL cases [2].

Bosutinib (SKI-606), a dual SRC and ABL inhibitor, differs from imatinib because it minimally inhibits KIT and platelet-derived growth factor receptor (PDGFR) [3]. The efficacy of bosutinib has been shown in phases 1 and 2 trials for all CML stages after treatments with only imatinib or with imatinib plus either nilotinib or dasatinib [4]. In the phase 3 BELA (Bosutinib Efficacy and Safety in Newly Diagnosed CML) trial, bosutinib patients could not reach the primary end point, which was to demonstrate superiority over imatinib in achieving complete cytogenetic responses by the 12th month of therapy. Bosutinib achieved cytogenetic and molecular responses more quickly than imatinib did; however, the survival rates were not significantly different. Grades 3–4 myelosuppression was reported when bosutinib was utilized as a first-line treatment (thrombocytopenia 14%, neutropenia 11%, and anemia 6%) [5].

Treating the lymphoid blast phase, which includes 20–30% of all blast phase CML cases, has been challenging ever since vincristine-prednisolone based therapy was first developed in 1970 [6]. The blast phase progression incidence in CML cases decreased from 20% to 1–1.5% after TKI therapy was introduced [7]. Central nervous system (CNS) involvement is frequently observed in Ph+ ALL and CML blastic crisis cases [8]. In CML, various chromosomal abnormalities can be detected in 2–17% of Ph-cells [9].

Treating older patients with ALL is still a dilemma; so far, very limited data are available. With the use of TKIs upfront in older patients in Ph+ALL, the survival and relapse-free survival were significantly improved (66% versus 43% and 58% versus 11% at 1 year, resp.) [10]. The mortality of induction chemotherapy varies widely (0% to 42%) due to infections and toxicities [11]. In two studies, 30% to 43% of patients older than age 60, compared to 18% to 22% of younger patients,
had a performance status of 2 or more [12]. For general management, it is essential to identify fit and unfit patients in treatment decisions [11].

Herein, we present a patient diagnosed with chronic-phase CML that progressed to the blast phase after treatment with imatinib, dasatinib, and nilotinib. The blast phase CML was treated successfully with bosutinib.

2. Case

A 72-year-old male patient presented, in 2006, with leukocytosis and hepatosplenomegaly. A complete blood cell analysis showed that the white blood cell count was $114 \times 10^9/L$, the hemoglobin was 10.4 g/dL, and the platelet count was $154 \times 10^9/L$. A peripheral blood smear showed populations of 33% neutrophils, 6% myeloblasts, 6% promyelocytes, 4% myelocytes, 15% metamyelocytes, 6% lymphocytes, 6% monocytes, 5% basophils, and 4% eosinophils. A bone marrow analysis showed hypercellularity with significant myeloid hyperplasia and 3% myeloblasts. There were no additional chromosomal abnormalities other than t(9;22)(q34;q11). The patient was diagnosed with chronic phase CML with a high Sokal score (1.21). He was initially treated with 400 mg imatinib/day; however, the dose was increased to 800 mg/day after 12 months because a cytogenetic analysis showed Ph+ > 35%. After 2 years of good drug compliance (in 2008), a major molecular response (MMR) was not achieved; therefore, 100 mg dasatinib/day was started. The patient achieved a complete cytogenetic response (CCyR) in the 6th month and MMR in the 12th month. The dasatinib dose was reduced to 70 mg/day and then 50 mg/day after a grade 3 thrombocytopenia was detected. The patient’s treatment was changed to 400 mg nilotinib/twice a day because he lost MMR and complete cytogenetic response two years after nilotinib initiation. A mutation analysis of the BCR-ABL1 kinase domain was negative. He achieved CCyR by the sixth month and MMR by the twelfth month with nilotinib.

In December 2013, the patient presented with fatigue and weight loss. His hemogram results were as follows: $56.5 \times 10^9$ WBCs/L, $14.6$ g Hb/dL, and $71 \times 10^9$ platelets/L. The bone marrow biopsy was consistent with 42% blasts diffusely positive with TdT, PAX5, and CD10. CD34 was partially and weakly expressed by blasts. MPO was negative on blastic cells.

Figure 1: The bone marrow was diffusely infiltrated with blasts. Blasts strongly expressed TdT, PAX5, and CD10. CD34 was partially and weakly expressed by blasts.
Figure 2: Initial axial enhanced T1-weighted MRI (a) show enhancement (arrow) of the clivus and occipital condyles corresponding to infiltration. Eight months later after systemic therapy axial enhanced T1-weighted MRI (b) shows significant reduction of the enhancement (arrow).

Figure 3: Initial sagittal nonenhanced T1-weighted MRI (a) show hypointensity of the clivus (arrow) and cervical vertebrae (short arrow) corresponding to infiltration. Eight months later after systemic therapy sagittal nonenhanced T1-weighted MRI (b) shows significant reduction of the hypointensity of the both clivus (arrow) and cervical vertebrae (short arrow).

Figure 4: Axial T2 weighted fat-suppressed images before (a) and after therapy (b) clearly show reduction of the pathological hyperintensity of the clivus and occipital condyles corresponding to infiltration.
CNS involvement. The clivus involvement disappeared during the follow-up period (Figures 2(b), 3(b), and 4(b)). The patient could not tolerate the methotrexate/vincristine maintenance therapy. We continued with 500 mg bosutinib every other day and followed up at the 3rd, 6th, and 12th months. At the 14th month follow-up, he had a complete hematological response, and his bone marrow was still in remission.

3. Discussion

Before the era of TKIs, the American Society of Hematology (ASH) recommended managing CML with conventional chemotherapy, IFN-alpha, and allogeneic stem cell transplantation in 1998 [13]. The European Leukemia Network (ELN) proposed 400 mg imatinib/day as a first-line treatment in their 2006 guidelines [14]. We initiated treatment as recommended and increased the dose to achieve a target response. In the 2009 ELN guidelines, a second-line treatment was suggested with second-line TKIs (nilotinib or dasatinib). Additionally, allogeneic stem cell transplantation was recommended for refractory/blastic or accelerated-phase patients [15]. We switched the treatment first to dasatinib and then to nilotinib for our patient.

Five years after diagnosis, our patient’s CML transformed to B cell ALL. In blastic transformation pathogenesis, the cells escaping from tyrosine kinase inhibition gain a growth advantage, which is the major issue that has been demonstrated for this disease [16]. Trisomy 8, isochromosome i(17q), trisomy 19, trisomy 21, trisomy 17, and deletion 7 are cytogenetic anomalies that have been reported to be responsible for blastic phase transformations [17, 18]. Trisomy 8, trisomy 10, and i(17q) have been detected in myeloid blast crisis cases, which is similar to our case, as monosomy 7 is common during lymphoid blastic crisis [17]. Under imatinib therapy, Kovitz et al. reported secondary myelodysplastic syndrome, acute myeloid leukemia, and ALL in 17 patients; however, monosomy 7 was the most common chromosomal anomaly reported [9]. In 21 of 272 patients (8%) that underwent imatinib treatment, some chromosomal anomalies developed, including trisomy 8, monosomy 5 or 7, and 20q− [19].

Blastic phase treatment is still challenging, and the median survival after a blastic phase diagnosis ranges from 7 to 11 months. Blastic crisis can be managed by decreasing the tumor burden through BCR-ABL elimination with TKIs [16]. Vignetti et al. reported that, upon using the GIMEMA LAL0201-B protocol, imatinib and steroid induction therapy in older ALL patients improved survival up to 20 months with minimal toxicity. The remission rate, survival rate, and disease-free survival rate were reported as 100%, 74%, and 48% after 1 year [20]. Because our patient had a poor performance status, and the toxicity was expected to be high in more intensive induction therapy, we modified the protocol with bosutinib because of the imatinib, dasatinib, and nilotinib refractoriness in our patient. Bosutinib has a comparable effect with nilotinib and dasatinib in CML [21].

In a 134-patient series (63 accelerated phase, 48 blastic phase, and 23 ALL), complete hematologic responses were achieved in 61% of the tumors that were in the accelerated phase and 3% of those that were in the blastic phase, whereas complete cytogenetic responses were detected in 33% of the accelerated phase and 29% of the blastic phase cases with bosutinib. These responses were maintained in 67% of the accelerated phase cases over one year; however, the responses were not durable in the blastic phase cases [22, 23].

On the 30th day of treatment, our patient developed pneumonia in a pancytopenic setting. Bosutinib is usually well-tolerated, with only mild gastrointestinal adverse events occurring [24]. Kantarjian et al. evaluated the safety of Bosutinib in 570 patients and showed 42% thrombocytopenia (30% grades 3-4), 28% anemia (14% grades 3-4), and 19% neutropenia (14% grades 3-4). Myelosuppression occurred after 22 days of initiation and lasted for a median of 14 days (range: 1–1,373 days). Myelosuppression was mostly detected in patients who received prior therapy. This myelosuppression was controlled with different treatment modifications, which included 46% temporarily stopping treatment, 32% with a dose reduction, 10% with growth factor support, and 1% with a transfusion requirement. Unfortunately, 7% of patients discontinued treatment because of severe myelosuppression [25, 26].

CNS involvement should be considered in all lymphoid blastic phase cases. Short-term responses can be achieved with intrathecal cytarabine and Mtx concurrently with radiotherapy [27]. Dasatinib has an advantage in CNS involvement, compared with imatinib, due to its SRC/BCR-ABL TK inhibition abilities and its blood-brain barrier penetration [28]. Although there are no reports that have demonstrated bosutinib’s efficacy in CNS involvement, we continued with the treatment after the suspected CNS involvement was determined because he had been unresponsive to other TKIs.

The blast phase in CML is a challenging condition due to a lack of treatment options and its low long-term response rates. This is the first case in literature demonstrating the effect of bosutinib in blast phase CML as an induction therapy in an older patient. Bosutinib, as a third-generation TKI, can be an alternative agent in elderly blastic-phase CML patients with a high tolerability profile and increased survival. If bosutinib is found to be effective in CNS involvement, it should be investigated further.

Conflict of Interests

The authors declare no conflict of interests.

References

[1] M. Baccarani, M. W. Deininger, G. Rosti et al., “European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013,” Blood, vol. 122, no. 6, pp. 872–884, 2013.
[2] D. G. Savage and K. H. Antman, “Imatinib mesylate—a new oral targeted therapy,” The New England Journal of Medicine, vol. 346, pp. 683–693, 2002.
[3] M. Puttini, A. M. L. Coluccia, F. Boschelli et al., “In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl” neoplastic cells,” Cancer Research, vol. 66, no. 23, pp. 11314–11322, 2006.
[4] BOSULIF (Bosutinib), Full Prescribing Information, Pfizer Labs, New York, NY, USA, 2012.

[5] J. E. Cortes, D. W. Kim, H. M. Kantarjian et al., “Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial,” Journal of Clinical Oncology, vol. 30, pp. 3486–3492, 2012.

[6] E. D. Thomas, R. A. Cliff, A. Fefer et al., “Marrow transplantation for the treatment of chronic myelogenic leukemia,” Annals of Internal Medicine, vol. 104, pp. 155–163, 1986.

[7] J. E. Sokal, “Evaluation of survival data for chronic myelocytic leukemia,” American Journal of Hematology, vol. 1, no. 4, pp. 493–500, 1976.

[8] H. Pfeifer, B. Wassmann, W.-K. Hofmann et al., “Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate,” Clinical Cancer Research, vol. 9, no. 13, pp. 4674–4681, 2003.

[9] C. Kovitz, H. Kantarjian, G. Garcia-Manero, L. V. Abruzzo, and J. Cortes, “Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia,” Blood, vol. 108, no. 8, pp. 2811–2813, 2006.

[10] A. Delannoy, E. Delabesse, V. Lheritier et al., “Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFRO9 study,” Leukemia, vol. 20, no. 9, pp. 1526–1532, 2006.

[11] N. Gökbuget, “How I treat older patients with ALL,” Blood, vol. 122, no. 8, pp. 1366–1375, 2013.

[12] O. Legrand, J.-P. Marie, Z. Marjanovic et al., “Prognostic factors in elderly acute lymphoblastic leukaemia,” British Journal of Haematology, vol. 97, no. 3, pp. 596–602, 1997.

[13] R. T. Silver, S. H. Woolf, R. H. Hlumann et al., “An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology,” Blood, vol. 94, no. 5, pp. 1517–1536, 1999.

[14] M. Fischer, M. Schmidt, S. Klingenberg, C. J. Eaves, C. Von Kalle, and H. Glimm, “Short-term repopulating cells with myeloid potential in human mobilized peripheral blood do not have a side population (SP) phenotype,” Blood, vol. 108, no. 6, pp. 2121–2123, 2006.

[15] M. Baccarani, J. Cortes, F. Pane et al., “Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 6041–6051, 2009.

[16] P. Armand, C. J. Gibson, C. Cutler et al., “A disease risk index for patients undergoing allogeneic stem cell transplantation,” Blood, vol. 120, no. 4, pp. 905–913, 2012.

[17] B. Johansson, T. Fioretos, and F. Mitelman, “Cytogenetic and molecular genetic evolution of chronic myeloid leukemia,” Acta Haematologica, vol. 107, no. 2, pp. 76–94, 2002.

[18] T. Mughal, J. Cortes, N. C. P. Cross et al., “Chronic myeloid leukemia—some topical issues,” Leukemia, vol. 21, no. 7, pp. 1347–1352, 2007.

[19] J. Medina, H. Kantarjian, M. Talpaz et al., “Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome—positive chronic myelogenous leukemia in chronic phase,” Cancer, vol. 98, no. 9, pp. 1905–1911, 2003.

[20] M. Vignetti, P. Fazi, G. Cimino et al., “Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol,” Blood, vol. 109, no. 9, pp. 3676–3678, 2007.

[21] G. Keller, P. Schafhausen, and T. H. Brümmedorf, “Bosutinib,” in Small Molecules in Oncology, U. M. Martens, Ed., vol. 184 of Recent Results in Cancer Research, pp. 119–127, Springer, Berlin, Germany, 2010.

[22] C. Gambacorti-Passerini, J. E. Cortes, H. J. Khoury et al., “Safety and efficacy of bosutinib in patients with AP and BP CML and Ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200,” Journal of Clinical Oncology, vol. 28, abstract 6509, 2010.

[23] C. Gambacorti-Passerini, H. M. Kantarjian, D. K. Kim et al., “Safety and efficacy of bosutinib in Philadelphia chromosome—positive advanced leukemia following imatinib and other tyrosine kinase inhibitors,” Leukemia, In press.

[24] J. E. Cortes, H. M. Kantarjian, T. H. Brümmedorf et al., “Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib,” Blood, vol. 118, no. 17, pp. 4567–4576, 2011.

[25] H. J. Khoury, J. E. Cortes, H. M. Kantarjian et al., “Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure,” Blood, vol. 119, no. 15, pp. 3403–3412, 2012.

[26] H. M. Kantarjian, “Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors,” Blood, vol. 123, no. 9, 2014.

[27] J. Cortes, “Central nervous system involvement in adult acute lymphocytic leukemia,” Hematology/Oncology Clinics of North America, vol. 15, no. 1, pp. 145–162, 2001.

[28] K. Porka, P. Koskenvesa, T. Lundán et al., “Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome positive leukemia,” Blood, vol. 112, no. 4, pp. 1005–1012, 2008.